Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 150c; affirms guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.68, $1.50 worse than the analyst estimate of $4.18. Revenue for the quarter came in at $901.98 million versus the consensus estimate of $953.95 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2024 EPS of $18.15-$19.35, versus the consensus of $18.95. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.2 billion, versus the consensus of $4.095 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform